ELITZUR, Sarah, Ajay VORA, Birgit BURKHARDT, Hiroto INABA, Andishe ATTARBASCHI, Andre BARUCHEL, Gabriele ESCHERICH, Brenda GIBSON, Hsi-Che LIU, Mignon LOH, V Moorman ANTHONY, Anja MOERICKE, Rob PIETERS, Anne UYTTEBROECK, Susan BAIRD, Jack BARTRAM, Shlomit BARZILAI-BIRENBOIM, Sandeep BATRA, Miriam BEN-HAROSH, Yves BERTRAND, Trudy BUITENKAMP, Kenneth CALDWELL, Ricardo DRUT, Ashley V GEERLINKS, Gil GILAD, John GRAINGER, Stephanie HAOUY, Nicholas HEANEY, Mary HUANG, Danielle INGHAM, Zdenka KŘENOVÁ, Michaela KUHLEN, Thomas LEHRNBECHER, Atsushi MANABE, Felix NIGGLI, Claudia PARIS, Shoshana REVEL-VILK, Pierre ROHRLICH, Mohamad G SINNO, Tomasz SZCZEPANSKI, Melanie TAMESBERGER, Rajasekharan WARRIER, Matthias WOLFL, Ronit NIREL, Shai IZRAELI, Arndt BORKHARDT and Kjeld SCHMIEGELOW. EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy. Blood. Washington DC, USA: American Society of Hematology, 2023, vol. 141, No 7, p. 743-755. ISSN 0006-4971. Available from: https://dx.doi.org/10.1182/blood.2022016975.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name EBV-driven lymphoid neoplasms associated with pediatric ALL maintenance therapy
Authors ELITZUR, Sarah (guarantor), Ajay VORA, Birgit BURKHARDT, Hiroto INABA, Andishe ATTARBASCHI, Andre BARUCHEL, Gabriele ESCHERICH, Brenda GIBSON, Hsi-Che LIU, Mignon LOH, V Moorman ANTHONY, Anja MOERICKE, Rob PIETERS, Anne UYTTEBROECK, Susan BAIRD, Jack BARTRAM, Shlomit BARZILAI-BIRENBOIM, Sandeep BATRA, Miriam BEN-HAROSH, Yves BERTRAND, Trudy BUITENKAMP, Kenneth CALDWELL, Ricardo DRUT, Ashley V GEERLINKS, Gil GILAD, John GRAINGER, Stephanie HAOUY, Nicholas HEANEY, Mary HUANG, Danielle INGHAM, Zdenka KŘENOVÁ (203 Czech Republic, belonging to the institution), Michaela KUHLEN, Thomas LEHRNBECHER, Atsushi MANABE, Felix NIGGLI, Claudia PARIS, Shoshana REVEL-VILK, Pierre ROHRLICH, Mohamad G SINNO, Tomasz SZCZEPANSKI, Melanie TAMESBERGER, Rajasekharan WARRIER, Matthias WOLFL, Ronit NIREL, Shai IZRAELI, Arndt BORKHARDT and Kjeld SCHMIEGELOW.
Edition Blood, Washington DC, USA, American Society of Hematology, 2023, 0006-4971.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30204 Oncology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 20.300 in 2022
RIV identification code RIV/00216224:14110/23:00131032
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1182/blood.2022016975
UT WoS 000968991200001
Keywords in English EBV-driven lymphoid neoplasms; pediatric ALL; maintenance therapy
Tags 14110317, 14110321, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 14/2/2024 09:44.
Abstract
The development of a second malignancy after the diagnosis of childhood acute lymphoblastic leukemia (ALL) is a rare event. Certain second malignancies have been linked with specific elements of leukemia therapy, yet the etiology of most second neoplasms remains obscure and their optimal management strategies are unclear. This is a first comprehensive report of non-Hodgkin lymphomas (NHLs) following pediatric ALL therapy, excluding stem-cell transplantation. We analyzed data of patients who developed NHL following ALL diagnosis and were enrolled in 12 collaborative pediatric ALL trials between 1980-2018. Eighty-five patients developed NHL, with mature B-cell lymphoproliferations as the dominant subtype (56 of 85 cases). Forty-six of these 56 cases (82%) occurred during or within 6 months of maintenance therapy. The majority exhibited histopathological characteristics associated with immunodeficiency (65%), predominantly evidence of Epstein-Barr virus-driven lymphoproliferation. We investigated 66 cases of post-ALL immunodeficiency-associated lymphoid neoplasms, 52 from our study and 14 additional cases from a literature search. With a median follow-up of 4.9 years, the 5-year overall survival for the 66 patients with immunodeficiency-associated lymphoid neoplasms was 67.4% (95% confidence interval [CI], 56-81). Five-year cumulative risks of lymphoid neoplasm- and leukemia-related mortality were 20% (95% CI, 10.2-30) and 12.4% (95% CI, 2.7-22), respectively. Concurrent hemophagocytic lymphohistiocytosis was associated with increased mortality (hazard ratio, 7.32; 95% CI, 1.62-32.98; P =.01). A large proportion of post-ALL lymphoid neoplasms are associated with an immunodeficient state, likely precipitated by ALL maintenance therapy. Awareness of this underrecognized entity and pertinent diagnostic tests are crucial for early diagnosis and optimal therapy.
Links
MUNI/A/1395/2022, interní kód MUName: Personalizovaná léčba v dětské onkologii: multimodální theranostický přístup a „N-of-1 clinical trials“
Investor: Masaryk University
PrintDisplayed: 21/7/2024 21:22